Associate Professor Liang QiaoAssociate Professor/Principal Research Fellow; Storr Liver Centre, The Westmead Institute for Medical Research; University of Sydney at Westmead Clinical School at Westmead Hospital; 176 Hawkesbury Road, Westmead, NSW 2145, Australia - Liver Cancer Group

 Phone+612 6876 3534

 Emailliang.qiao(at)sydney.edu.au

Funding

• NHMRC
• Cancer Council NSW
• Cancer Institute NSW

Collaborators

• Wei Duan, Professor of Cancer Programme, School of Medicine, Faculty of Health, Deakin University, Australia (using aptamers to target liver cancer stem cells)
• Dr Michael O'Connor, Associate Professor and President of Australasian Society for Stem Cell Research, University of Western Sydney (iPSCs in chronic liver diseases)
• Professor George Yeoh, School of Chemistry & Biochemistry, The University of Western Australia (liver cancer)
• Jiangao Fan, Professor & Director of Gastroenterology Department, Xinhua Hospital Affiliated to SJTU School of Medicine, Shanghai, China (chronic liver diseases, NASH, liver cancer)
• Yumin Li, Professor of Hepatobiliary Surgery, and the President of the Second Hospital, Dean of School of Medicine, Vice Chancellor of Lanzhou University, China (liver cancer, GI cancer, tissue bank, iPSC bank)
• Yongning Zhou, Professor and Director of Gastroenterology Department, Hospital Deputy President, the First Hospital of Lanzhou University, China (liver cancer, GI cancer)
• Yun Dai, Associate Professor, Department of Gastroenterology, Peking University First Hospital, Beijing, China (colorectal cancer)
• Rongxin Zhang, Professor and Director, Laboratory of Immunology and Inflammation, Research Center of Basic Medical Science, Tianjin Medical University, Key Laboratory of Immune Microenvironment and Diseases, Ministry of Education of China, Tianjin, China (GI and liver cancers, immune therapy for cancer)
• Li-Jing Wang, Professor of Pathology, Director, Vascular Biology Research Institute, Guangdong Pharmaceutical University, China (experimental therapy for GI and liver cancers)
• Nattiya Hirankarn, Professor of Medicine and Immunology, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (HCV- and HBV-related liver cancer)
• Dr Nirupma Trehanpati, Additional Professor, Clinical and Cellular Transplant Immunology & Department of Research, Institute of Liver and Biliary Sciences, New Delhi, India (Targeting CSCs as a therapeutic approach for liver cancer)
• Hongliang Li, Professor and Director, Animal Research Center, Wuhan University, Collaborative Innovation Center of Model Animal, Wuhan University (Animal models of liver cancer)